Jasper Therapeutics, Inc. (JSPR)
NASDAQ: JSPR · Real-Time Price · USD
0.9120
-0.0005 (-0.05%)
May 13, 2026, 11:06 AM EDT - Market open
Company Description
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States.
The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells.
It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California.
Jasper Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jeetinder Mahal |
Contact Details
Address: 2200 Bridge Pkwy, Suite 102 Redwood City, California 94065 United States | |
| Phone | 650 549 1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1788028 |
| CUSIP Number | 471871103 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal M.B.A. | President, Chief Operating Officer, Chief Executive Officer and Director |
| Thomas G. Wiggans | Executive Chairman |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board and Director |
| Alex Gray | Head of Investor Relations |
| Matthew Ford | Senior Vice President of Human Resources |
| Dr. Luca Di Noto Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | SCHEDULE 13G/A | Filing |
| May 8, 2026 | SCHEDULE 13G/A | Filing |
| Apr 30, 2026 | 10-K/A | [Amend] Annual report |
| Mar 30, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | SCHEDULE 13G | Filing |
| Feb 18, 2026 | SCHEDULE 13D/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G | Filing |
| Feb 11, 2026 | SCHEDULE 13G | Filing |